Last reviewed · How we verify
Placebo to salbutamol
Salbutamol is a beta-2 adrenergic agonist that relaxes airway smooth muscle by activating beta-2 receptors, causing bronchodilation.
Salbutamol is a beta-2 adrenergic agonist that relaxes airway smooth muscle by activating beta-2 receptors, causing bronchodilation. Used for Acute bronchospasm relief in asthma, Acute bronchospasm relief in chronic obstructive pulmonary disease (COPD).
At a glance
| Generic name | Placebo to salbutamol |
|---|---|
| Sponsor | Novartis |
| Drug class | Short-acting beta-2 agonist (SABA) |
| Target | Beta-2 adrenergic receptor (ADRB2) |
| Modality | Small molecule |
| Therapeutic area | Respiratory |
| Phase | Phase 3 |
Mechanism of action
Salbutamol binds to and activates beta-2 adrenergic receptors on airway smooth muscle cells, triggering a cascade that increases intracellular cAMP levels. This leads to smooth muscle relaxation and rapid bronchodilation, relieving airway obstruction. It is a short-acting bronchodilator used for acute relief of bronchoconstriction in asthma and COPD.
Approved indications
- Acute bronchospasm relief in asthma
- Acute bronchospasm relief in chronic obstructive pulmonary disease (COPD)
Common side effects
- Tremor
- Headache
- Nervousness
- Palpitations
- Tachycardia
Key clinical trials
- Study of Lunsekimig (SAR443765) Compared With Placebo in Adults With High-risk Asthma (PHASE2)
- A Randomized, Double-Blind, Placebo-Controlled Trial on Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Combination in Participants 12 Years and Older With Asthma (PHASE3)
- Effects of Salbutamol in Athletes and Implications for Screening and Sports (NA)
- A Study to Investigate the Effect on Lung Function of BDA Formulated With a Next Generation Propellant Compared With an Approved Asthma Treatment (BDA With HFA Propellant) in Participants With Asthma (PHASE3)
- A Study to Evaluate the Efficacy and Safety of QVM149 (Indacaterol Acetate / Glycopyrronium Bromide / Mometasone Furoate) Versus Salmeterol Xinafoate/Fluticasone Propionate in Children From 12 Years to Less Than 18 Years of Age With Asthma. (PHASE3)
- Effect of Intraoperative Salbutamol Administration on Mechanical Power and Respiratory Mechanics in Obese Patients Undergoing Laparoscopic Bariatric Surgery (NA)
- the Inhaled β2-adrenergic Receptor Agonist for Transient Tachypnoea of the Newborn (the REFSAL Trial) (PHASE3)
- Cardiovascular Consequences of Inhaled Short-acting Beta-agonist Use (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Placebo to salbutamol CI brief — competitive landscape report
- Placebo to salbutamol updates RSS · CI watch RSS
- Novartis portfolio CI